Sign inJoin waitlistJoin the waitlist

Ramya Ramaswami

Lasker Clinical Research Scholar · Clinical Center at the National Institutes of Health

Credentials: · · · ·

History

Clinical Center at the National Institutes of Health
Present

Medical Oncology
Internal Medicine
Columbia University, Mailman School of Public Health
IMPERIAL COLL, LONDON FAC OF MED, LONDON, UNITED KINGDOM

Research

The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
Journal of Hepatology · 2017 · 345 citations
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study
JAMA Oncology · 2019 · 205 citations
Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA
Proceedings of the National Academy of Sciences of the United States of America · 2018 · 150 citations

Kathryn Lurain
50 papers · 5 as a fellow
Robert Yarchoan
47 papers
TU
Thomas Uldrick
28 papers
Hao-Wei Wang
10 papers
PG
Priscila Hermont Barcellos Goncalves
10 papers
MP
Mark Polizzotto
9 papers
Ralph Mangusan
9 papers
Armando Filie
7 papers
Elaine Jaffe
7 papers
Stefania Pittaluga
7 papers
ES
Elad Sharon
6 papers
Constance Yuan
5 papers

Grants

Targeted Therapies for Kaposi Sarcoma and KSHV-Multicentric Castleman Disease
National Cancer Institute · ZIA
Contact PI · $3.8M · Division of Basic Sciences - Nci

Clinical trials

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2037
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2034
Natural History Study of Kaposi Sarcoma
Principal investigator · Recruiting
National Cancer Institute (NCI)
2024–2036
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2032